FDA Alerts
FDA Drug Safety Communication: Rosiglitazone-containing Medicines
The U.S. Food and Drug Administration (FDA) is informing the public of new restrictions to the prescribing and use of rosiglitazone-containing medicines.
The Warning is on the Label
The FDA is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide.